1. Targeting Monoclonal Antibodies to the Tumor Microenvironment for Cancer Therapy/Immunotherapy
    2. An Advanced Phase 1/2 Study using an XC-Targeted Gene Therapy Vector for Chemotherapy Resistant Sarcoma


    1. New Cancer Therapies for the 21st Century: A Two Decade Review of Approved Drugs and Drugs in Development in the United States
    2. Giant-cell tumor of bone: treatment options and role of denosumab
    3. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab
    4. First-Line Aldoxorubicin vs Doxorubicin in Metastaticor Locally Advanced Unresectable Soft-Tissue Sarcoma A Phase 2b Randomized Clinical Trial


    1. Phase II Study of the Safety and Antitumor Activityof the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft-Tissue Sarcoma


    1. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft-tissue sarcoma receiving doxorubicin and ifosfamide
    2. Trabectedin is a feasible treatment for soft-tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials


    1. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy


    1. Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery
    2. A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol
    3. A phase I/II study of intravenous Rexin-G and Reximmune-C for cancer immunotherapy: The GeneVieve protocol
    4. Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer


  1. Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma

Next, meet our doctors.